Page 75 - The Flying Publisher Guide to Hepatitis C Treatment

Searching for new antiviral therapies | 75

Preliminary data show that DAAs induce a more rapid decline in
the VL than the one seen with PegIFN/RBV.

Table 4.3 – The most promising new therapeutical options for CHC
(as of June 2011) *
Category Mechanism Example Manufacturer Phase
Direct-acting NS3/NS4A BI201335 Boehringer III
antivirals protease TMC435 Medivir/Tibotec III
inhibitors
GS-9256, -9451 Gilead II
Danoprevir Intermune/Roche II
Vaniprevir Merck II
ACH-1625 Achillon Pharm. II
ABT 450 Abbott/Enanta II
BMS-650032 Bristol-Myers Squibb IIa
NS5B polymerase Mericitabine Roche/Pharmaset II
inhibitors, PSI-7977 Pharmaset II
nucleoside
analogs IDX 184 Idenix II
NS5B polymerase Filibuvir Pfizer II
inhibitors, GS-9190 Gilead II
non-nucleoside
analogs VX 222 Vertex II
ABT 333, -072 Abbott II
Setrobuvir Anadys Pharm. II
NS5A inhibitors BMS-790052 Bristol-Myers Squibb II
ABT 267 Abbott II
AZD 7295 AstraZeneca II
Host Cyclophilins Alisporivir Novartis/Debiopharm III
targeting inhibitors
agents Virus entry MBL-HCV1 The University of II
inhibitors human Massachusetts Medical
monoclonal School
antibody
ITX 5061 iTherX II
Bavituximab Peregrine Pharm. II
* For more information, see http://hcvdrugs.com and the manufacturers' web
sites presented at the end of the chapter.